We need access to data on all clinical trials, not just some

Although the BMJ and GlaxoSmithKline’s initiatives are highly commendable,1 these initiatives would not completely solve the problem of reporting bias. Comprehensive access to clinical trial data can be ensured only by the routine release of all clinical study reports (CSRs) after drug approval. In 2010, the European Medicines Agency (EMA) introduced a new policy on the release of clinical trial data submitted to the agency.2 However, the data format is …